China Feihe Xingfeifan: premium infant formula for Chinese families

China Feihe’s Xingfeifan ultra-premium infant formula targets Chinese parents seeking high-end nutrition, with multiple stage-specific recipes and strong market traction in China’s domestic milk powder segment.

Responsible: ad hoc news Lifestyle & Consumer Desk. Reviewed prior to publication on June 12, 2026 at 1:17 PM ET. Details in the imprint.

China Feihe’s Xingfeifan infant formula line sits in the ultra-premium segment of China’s baby nutrition market, aimed at parents willing to pay more for domestic, research-driven recipes. The brand offers stage-specific formulas designed to support different phases of early childhood development, and is positioned above the company’s core Astrobaby and Feifan series by price and branding. While Xingfeifan products are primarily sold in mainland China, they anchor Feihe’s strategy in higher-margin infant milk powder and illustrate why the group remains closely watched by consumers and private investors alike.

What Xingfeifan infant formula offers parents

Xingfeifan is one of China Feihe’s flagship ultra-premium lines, typically marketed for infants and toddlers from birth up to 3 years, with distinct stages that align with Chinese pediatric guidelines. According to China Feihe’s product information, the brand emphasizes a nutritional profile designed to be closer to breast milk, with added ingredients such as structured lipids, nucleotides and prebiotic fibers in selected recipes to support digestion and immune function. Packaging is usually in metal cans, often around 800 g per unit, reflecting the standard size used in China’s infant formula market. The formulas are based on cow’s milk, processed and blended in Feihe’s domestic production facilities that have passed China’s regulatory approval for infant milk powder.

In company presentations, Feihe highlights that its infant formula ranges, including Xingfeifan, are built on over 50 years of experience in dairy processing and close cooperation with research institutes in China and overseas. The firm has repeatedly stressed its focus on formulas tailored to Chinese infants’ nutritional needs, arguing that differences in diet, climate and genetics justify localized formulations. Xingfeifan, as an ultra-premium range, benefits from this positioning and is typically promoted in maternity-and-baby specialty stores and through healthcare channels, which remain critical sales locations for high-end formula in China. For parents, this means the product is often recommended at the point of consultation or retail counseling rather than being picked off a generic supermarket shelf.

Price-wise, Xingfeifan generally sells at a premium to Feihe’s mainstream lines and to many imported mass-market competitors, although exact shelf prices vary by region, retailer and ongoing promotions. Industry reporting on China’s infant formula market indicates that ultra-premium domestic brands can reach price levels comparable to, or slightly below, imported European and Oceania brands per 800 g can. For international readers, this places Xingfeifan clearly in the upper tier of infant nutrition spending for Chinese households, where willingness to invest in baby-related products remains comparatively high despite pressure from lower birth rates. While China Feihe does not quote a universal manufacturer’s suggested retail price in US dollars, third-party listings and retail scans suggest that a can of an ultra-premium domestic formula like Xingfeifan typically converts to the equivalent of roughly $40 to $60 per can at prevailing exchange rates, depending on channel and stage. These figures are indicative only and can move with currency, discounting and local competition.

From a formulation standpoint, Xingfeifan competes in a crowded arena of value-added claims in China’s baby-nutrition sector. Many premium formulas now highlight specialty ingredients, such as specific blends of DHA and ARA fatty acids for brain and vision development, or customized protein structures for easier digestion; Feihe’s marketing materials for its high-end lines follow this pattern, emphasizing digestion comfort, stool softness and reduced risk of constipation for some series. Regulatory disclosures and market surveillance reports underscore that infant formula in China must comply with stringent national standards on macronutrient and micronutrient content, so differences between brands tend to be about optional functional ingredients, sourcing stories and perceived quality. For parents evaluating Xingfeifan, label comparison with other formulas on protein, fat, carbohydrate and vitamin-mineral content remains an important step, alongside consultation with pediatricians and local health professionals.

Distribution for Xingfeifan is heavily China-centric, reflecting Feihe’s focus on its domestic base. The company derives the vast majority of its revenue from infant milk formula sold in mainland China, with leading market share in several northeastern provinces. Xingfeifan features in this mix as part of Feihe’s ultra-premium portfolio, complementing other high-end series in the company’s ladder of offerings. Sales channels typically include mother-and-baby specialty chains, regional distributors, Feihe-branded stores and major Chinese e-commerce platforms; cross-border and export availability to the US remains limited and is often confined to parallel imports via third-party sellers. For US-based shoppers, this means that Xingfeifan is not widely available through mainstream American retail chains and may appear only sporadically on global marketplaces, where authenticity, storage conditions and import compliance should be checked carefully.

For China Feihe, high-end infant formula like Xingfeifan plays a strategic role at a time when China’s birth rate is declining and competition is intensifying. Company filings and analyst commentary point out that the firm is leaning more heavily on premium and ultra-premium products to sustain profitability, even if overall volumes in the market soften. Investors watching the company often look at indicators such as average selling price, product mix and market share in premium segments as proxies for the health of brands like Xingfeifan. Shares of China Feihe (KYG2108Y1052, ticker 6186) last traded in the US over the counter; the stock is primarily listed in Hong Kong, and recent price data are quoted in Hong Kong dollars on the local exchange.

Snapshot: China Feihe Xingfeifan

• Product: China Feihe Xingfeifan infant formula
• Manufacturer: China Feihe
• Category: Lifestyle & consumer infant nutrition
• Launch date: Ultra-premium line introduced in the 2010s, with subsequent recipe and packaging updates for different stages
• MSRP / Price: Varies by stage and Chinese retailer; indicative ultra-premium range roughly equivalent to $40-$60 per 800 g can at prevailing exchange rates (subject to discounts and regional differences)
• Availability: Primarily sold in mainland China through mother-and-baby specialty stores, Feihe-affiliated outlets and Chinese e-commerce; limited cross-border listings for international buyers
• Target audience: Parents of infants and toddlers up to around 3 years seeking China-made, premium infant formula
• Key feature / USP: Ultra-premium, China-focused formula range with stage-specific recipes and added functional ingredients positioned as tailored to Chinese infants’ nutritional needs

This article was created with a.i. assistance and editorially reviewed. Product information is provided without warranty; prices and availability may change at any time. Not investment advice, not a buy or sell recommendation. Trading in securities carries risks up to the total loss of capital.